NCT05029102View on ClinicalTrials.gov

TAS-102 and Anlotinib in ≥3 Lines mGC

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Gastric Cancer
Interventions
DRUG

TAS 102

35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle

DRUG

Anlotinib

10mg，per oral，once daily，days 1-14 of each 21-day cycle

Trial Locations (1)

310003

RECRUITING

First affiliated hospital, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER